11.25.24 -- Picking The Right CDMO Partner For Your Project

Learn about our new facility expansions, enhanced filling capacity, and advanced packaging capabilities that are designed to support and elevate your drug development projects.

Review our high-quality GMP manufacturing capabilities, featuring an isolator-based filling platform and fill-finish capacity for vials, syringes, and cartridges, and recent facility expansion.

Enhance your injectable projects with our expertise and expanded capacity to meet the demand for vials, pre-filled syringes, and cartridges from pre-clinical development to commercial launch.

Our injectables CDMO expertise can support your molecule, with a team skilled in complex formulations, over 20 commercial products, a 40+ year regulatory history, and a new isolator filler capacity.

Jeff Clement, Executive Director of Technical Sales Drug Product Development and Manufacturing, outlines our global sterile fill-finish and lyophilization capabilities, investments, and expansions.

Our full-service model enables us to collaborate with partners on sterile injectable projects, delivering quality products for both early clinical stages and large-scale commercial supply.

Explore our exceptional injectable manufacturing capabilities, featuring our high-speed, multi-purpose fill-finish line for vials, syringes, and cartridges at our San Diego facility.

Partner with us to access the critical services that drive your success — supporting everything from technical and development batches to Phase 1 clinical trials and product launch.

Let us support your high-quality medicines with integrated offerings in mammalian drug substances and drug products, including our fill and finish services for vials, syringes, cartridges, and auto-injectors.

Alcami provides sterile drug product fill-finish services, including formulation development, complex formulations, clinical manufacturing, batch scale-up, and commercial production.

See how our specialized manufacturing site in Sanford, NC — backed by over 35 years of expertise in mAb production — can expedite the delivery of your groundbreaking therapies to patients.

We're poised to be your next growth engine with our commitment to quality, speed, and agility, as we expand our facilities and invest in innovative modalities to meet your large molecule needs.

We have the capabilities, competitive advantages, and capacity to onboard new projects across two facilities: Waltham, MA, operational since 2020, and Vilnius, Lithuania, established in 2004.

Explore our global production network, advanced aseptic filling, in-house analytics, and the expertise that has driven 47 biopharmaceuticals to market success.

Rasmus Pedersen, Ph.D., outlines strategies to expand large-molecule production capacity to meet the global medicine demand, noting the current gap that leaves 2 billion people without access.

Gain valuable insights into our mammalian development services, manufacturing solutions, upcoming capacity availability, as well as updates on expansion timelines for external clients.

Business Head of Biologics and Vaccines Evan Pasenello shares how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs.

We offer adaptable, comprehensive solutions to advance your program seamlessly from IND-enabling studies through to late-stage commercial production.

Senior Business Development Director Rose Rhomberg presents an in-depth look at Cytovance’s capabilities and highlights the available capacity designed to accelerate your goals.

Leverage our flexible solutions and access to proprietary CHO-K1 cell lines in our state-of-the-art cGMP suites equipped with both single-use and traditional stainless steel bioreactors.

Utilize our integrated CRO and CDMO services for developing and manufacturing complex biologics, bioconjugates, and ADCs, ensuring high-quality products and data packages.

This presentation underscores the essential role of comprehensive characterization in ensuring that ADCs not only meet regulatory standards but also achieve therapeutic goals.

We've expanded our U.S. and Germany sites to offer end-to-end services for product development, clinical and commercial fill/finish, and ADC conjugation and purification by 2025.

Partner with us for full-service ADC development and production, from feasibility to GMP manufacturing, with industry-leading standards and flexible capacities.

Advance ADC development with the SMARTag® Platform, combining precision bioconjugation and a linker-payload library to enhance the therapeutic index and accelerate timelines.

Streamline your ADC project with the Proveo™ alliance, offering seamless, end-to-end support across antibody production, bioconjugation, and aseptic fill.